IP Library Granted Patent US 7,683,092
Granted Patent B2
US 7,683,092 · App. 11/885,842 · Granted Mar 23, 2010

Crystalline forms of antidiabetic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,683,092
App. No.
11/885,842
Granted
Mar 23, 2010
Kind
B2
Abstract

Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases.

Claims (6)

1. A compound having the name (2R)-2-{3-[3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}butanoic acid, the structural formula I,

and characterized as being a crystalline free acid dehydrate, and further characterized as having at least one XRPD peak selected from the group consisting of: 16.8°, 19.6°, 5.7°, 22.4°, 7.7°, 15.2°, 24.6°, 11.2°, and 22.8° 2θ.

2. A pharmaceutical composition in the form of a tablet or capsule comprising a compound in accordance with claim 1 in combination with one or more pharmaceutically acceptable carriers or excipients.

3. A compound having the name (2R)-2-{3-[3-(4-methoxybenzoyl) -2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}butanoic acid, the structural formula I,

and characterized as being a crystalline free acid dehydrate, and further characterized as having at least one chemical shift value in the solid-state carbon-13 CPMAS NMR spectrum having chemical shift values selected from the group consisting of 11.1, 56.2, 190.7, 13.9, 78.3, 174.2, 164.1, and 157.6 ppm.

4. A pharmaceutical composition in the form of a tablet or capsule comprising a compound in accordance with claim 3 in combination with one or more pharmaceutically acceptable carriers or excipients.

Assignments (5)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Feb 3, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023891/0395 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023906/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2008
From: ZHAO, DALIAN; LEYES, AQUILES E.; MARCOUX, JEAN-FRANCOIS; BOARDMAN, DAVID
To: MERCK & CO., INC.
Reel/Frame 020628/0865 →